GK02

Phase 1Small molecule

BBeijing Geekgene Technology Co., LTD

GK02 is one of 11 small molecule programs targeting Ascites. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AscitesRecruiting

AscitesPhase 1

Recruiting

Competition

Competitive Landscape

12 competitors in Ascites

#DrugCompanyPhaseTrials

Aldactone

Samsca

1 3

Inderal

WWyeth-Lederle Vaccines

Approved

1 4

Farxiga

AstraZeneca

Phase 2

2 5

Albumin

LLaboratoire français de Fractionnement et de Biotechnologies

Phase 3

2 6

Proamatine

Takeda

Preclinical

2 7

Keytruda

Merck & Co.

Preclinical

1 8

Opdivo

Bristol-Myers Squibb

Preclinical

1 9

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 10

NK042

SShanghai NK Cell Technology Co., LTD

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Ascites

NCT07378436

Clinical

Trials by Indication[1]

Ascites1 trial

A Clinical Study of GK02 in Malignant Ascites

Recruiting·BBeijing Geekgene Technology Co., LTD·Phase 1·NCT07378436·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GK02. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GK02 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GK02. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Geekgene Technology Co., LTD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: BBeijing Geekgene Technology Co., LTD

GK02

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Ascites1 trial

References

Drug Info

Quick Facts

Related News